ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
0,00%
Bitcoin
67.745,12
0,03%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. ImmunoPrecise Antibodies Ltd (IPA)

  7. ImmunoPrecise Antibodies Ltd (IPA) News

IPA

ImmunoPrecise Antibodies (IPA)

ImmunoPrecise Antibodies Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:IPA
DatumZeitQuelleÜberschriftSymbolFirma
28/03/202419h35Business WireInterSystems et BioStrand, filiale d’IPA, collaborent au lancement de l’intégration innovante de la recherche vectorielle et de LENSai dans les applications de soins de santé pilotées par l’IANASDAQ:IPAImmunoPrecise Antibodies Ltd
28/03/202412h02Business WireInterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare ApplicationsNASDAQ:IPAImmunoPrecise Antibodies Ltd
20/03/202418h52Business WireIPA acquiert l'instrument Carterra LSA® pour améliorer la découverte d'anticorps et renforcer ses développements en matière d'IANASDAQ:IPAImmunoPrecise Antibodies Ltd
20/03/202412h02Business WireIPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI DevelopmentsNASDAQ:IPAImmunoPrecise Antibodies Ltd
15/03/202400h39Business WireIPA présente ses résultats financiers et les récents points forts de son activité pour le troisième trimestre de l’exercice 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
14/03/202413h05Business WireIPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
07/03/202421h24Business WireBioStrand, filiale d'IPA, annonce une avancée majeure dans les sciences du vivant avec son Advanced Foundation AI Model utilisant l'empilement LLM et la technologie HYFTNASDAQ:IPAImmunoPrecise Antibodies Ltd
07/03/202417h19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
07/03/202413h02Business WireIPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT TechnologyNASDAQ:IPAImmunoPrecise Antibodies Ltd
04/03/202422h50Business WireL'IPA publiera ses résultats financiers et les faits marquants de sa récente activité pour le troisième trimestre de l'exercice 2024, le 14 mars 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
04/03/202414h01Business WireIPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
23/02/202423h29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
23/02/202423h26Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IPAImmunoPrecise Antibodies Ltd
15/02/202421h12Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:IPAImmunoPrecise Antibodies Ltd
10/01/202419h53Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IPAImmunoPrecise Antibodies Ltd
10/01/202419h33Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IPAImmunoPrecise Antibodies Ltd
14/12/202321h08Business WireIPA présente ses résultats financiers et les récents points forts de son activité pour le deuxième trimestre de l’exercice 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
14/12/202314h48Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
14/12/202314h38Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
14/12/202314h03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
14/12/202314h01Business WireIPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
09/12/202303h57Business WireIPA annonce la clôture d'une offre publique d'actions ordinaires pour un montant de 1 265 million de dollarsNASDAQ:IPAImmunoPrecise Antibodies Ltd
08/12/202323h11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
08/12/202323h00Business WireIPA Announces Closing of $1.265 Million Public Offering of Common SharesNASDAQ:IPAImmunoPrecise Antibodies Ltd
07/12/202322h53Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IPAImmunoPrecise Antibodies Ltd
06/12/202323h19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
06/12/202313h57Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
06/12/202313h00Business WireIPA annonce le prix des actions ordinaires de son émission publique de 1,1 million USDNASDAQ:IPAImmunoPrecise Antibodies Ltd
06/12/202313h00Business WireIPA Announces Pricing of $1.1 Million Public Offering of Common SharesNASDAQ:IPAImmunoPrecise Antibodies Ltd
06/12/202312h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
 Showing the most relevant articles for your search:NASDAQ:IPA

Kürzlich von Ihnen besucht

NASDAQ
CLSM
Cabana Target Leading Se...
NASDAQ
AAWUEXX
Bank of Montreal Point t...
EU
6884S
6884S
EU
PEV4P
Banque Palatine null
NASDAQ
GRPANX
RetirePilot Moderate 203...
NYSE
KSO.L
Str PD 7.125 Ibm
BIT
P1Z0I5
NLBNPIT1Z0I5 20991231 1....
USOTC
XVIPF
Xvivo Perfusion AB (PK)
NASDAQ
FSUPLX
High Dividend Equity Por...
TSXV
GGM
Granada Gold Mine
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten